Tranzyme, Inc.
5001 South Miami Boulevard
Suite 300
Durham,
NC 27703
United States - Map
Phone: 919-474-0020
Fax: 919-474-0025
Website: http://www.tranzyme.com
| Index Membership: | N/A | | Sector: | Healthcare | | Industry: | Drug Manufacturers - Major | | Full Time Employees: | 29 |
|
Tranzyme, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of mechanism-based therapeutics primarily in the United States. The companys pre-clinical product pipeline includes TZP-201, a motilin antagonist, for the treatment of various forms of moderate-to-severe diarrhea; and TZP-301, a ghrelin antagonist, for the treatment of metabolic diseases. The company has strategic collaboration with Bristol-Myers Squibb Company to discover, develop, and commercialize additional novel compounds. Tranzyme, Inc. was founded in 1998 and is headquartered in Durham, North Carolina. Key Statistics
| |
| | Pay | Exercised | Mr. Vipin K. Garg Ph.D.,
40
Chief Exec. Officer, Pres and Director | 382.00k | 0.00 | Mr. David S. Moore ,
39
Chief Bus. Officer | 258.00k | 0.00 | Dr. Helmut Thomas Ph.D., DABT,
62
Sr. VP of Research & Preclinical Devel. | 276.00k | 0.00 | Dr. Franck S. Rousseau M.D.,
56
Chief Medical Officer | 340.00k | 0.00 | Ms. Rhonda L. Stanley ,
53
Principal Financial Officer, Principal Accounting Officer and Corp. Controller | N/A | N/A |
|
| | Amounts are as of 2012-12-30 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year. | | Currency in USD. |
|
0.02(3.57%) 3:59PM EDT|After Hours
:
0.51